Pulmatrix Inc Total Assets
Pulmatrix Inc total assets. Based on the latest financial reports, Pulmatrix Inc (PULM) holds total assets worth $4.50 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Pulmatrix Inc for the company's overall valuation and market capitalisation.
Total Assets of Pulmatrix Inc (2012–2025)
Total assets of Pulmatrix Inc from 2012 to 2025. This chart illustrates how Pulmatrix Inc's total assets have evolved over time, based on quarterly financial data. See PULM live share price for real-time trading data and today's change.
Pulmatrix Inc - Asset Composition Analysis
Pulmatrix Inc Total Assets Breakdown (December 2025)
Pulmatrix Inc total assets breakdown as of December 2025. Pulmatrix Inc's total assets of $4.50 Million consist of 99.8% current assets and 0.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Pulmatrix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PULM working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pulmatrix Inc's current assets represent 99.8% of total assets in 2025, an increase from 67.6% in 2012.
- Cash Position: Cash and equivalents constituted 98.8% of total assets in 2025, up from 64.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Pulmatrix Inc Competitors by Total Assets
Key competitors of Pulmatrix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Pulmatrix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.96 | 8.90 | 8.74 |
| Quick Ratio | 4.96 | 8.90 | 8.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.58 Million | $7.14 Million | $53.55 Million |
Pulmatrix Inc - Advanced Valuation Insights
This section examines the relationship between Pulmatrix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.30 |
| Latest Market Cap to Assets Ratio | 1.24 |
| Asset Growth Rate (YoY) | -58.4% |
| Total Assets | $4.14 Million |
| Market Capitalization | $5.11 Million USD |
Valuation Analysis
Above Book Valuation: The market values Pulmatrix Inc's assets above their book value (1.24x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Pulmatrix Inc's assets decreased by 58.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pulmatrix Inc (2012–2025)
The table below shows the annual total assets of Pulmatrix Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $4.14 Million | -58.37% |
| 2024-12-31 | $9.94 Million | -70.72% |
| 2023-12-31 | $33.96 Million | -17.08% |
| 2022-12-31 | $40.95 Million | -30.37% |
| 2021-12-31 | $58.82 Million | +54.10% |
| 2020-12-31 | $38.17 Million | +5.74% |
| 2019-12-31 | $36.10 Million | +145.18% |
| 2018-12-31 | $14.72 Million | -7.85% |
| 2017-12-31 | $15.98 Million | -4.11% |
| 2016-12-31 | $16.66 Million | -62.87% |
| 2015-12-31 | $44.87 Million | +188.09% |
| 2014-12-31 | $15.58 Million | 0.00% |
| 2013-12-31 | $15.58 Million | +10424.32% |
| 2012-12-31 | $148.00K | -- |
About Pulmatrix Inc
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.… Read more